Polluters migrate to China's poor areas
Bo Zhang and Cong Cao argue that China's citizens should have a legal right to safeguard the quality of their environment (Nature 517, 433-434; 2015) . The wealthy would stand to benefit most from such a public litigation system, causing pollution producers to migrate to poorer areas.
Heavy industry in China is already moving out of developed eastern regions to the west (see X. Bai et al. Nature 509, 158-160; 2014) , where it is damaging the local ecology. Industrial waste slag has eroded a nature conservation area in Xinjiang (see go.nature. com/68e1lo; in Chinese), for example, and discharge from factories has severely polluted part of the Tengger Desert at the border of the Inner Mongolia and Ningxia regions (see go.nature. com/nlfbrs; in Chinese).
Environmental 27-29; 2015) . The real solution is proper initial validation of antibodies.
In my view, the reproducibility problem is better addressed by identifying the good antibodies and the reputable companies that develop, validate and manufacture them -as astute scientists do now. Also, journals need to mandate the provision of detailed validation data, protocols and antibody sources (clone, catalogue number). Independent websites enabling the submission of antibody data and consumer feedback would also help.
The biggest investment in developing a good monoclonal antibody is the extensive work
Antibodies: validate recombinants too
Recombinant antibodies are pure proteins with minimal batchto-batch variability, so could provide an important element of antibody standardization (A. Bradbury et al. Nature 518, 27-29; 2015) . However, they must still be functionally validated if they are to help solve the reproducibility crisis.
Vendors and researchers would have to optimize their recombinant antibodies for specific applications, because of the inherent complexity of these molecules and their ability to bind non-specifically to other proteins carrying similar immunological sequences.
Suppliers and users of such antibodies will need specialized training in this validation and optimization, particularly in experimental design and the extensive use of controls. Leonard P. Freedman Global Biological Standards Institute, needed to validate specificity and sensitivity across all relevant applications. Unlike therapeutic antibodies, most research antibodies are not sequencepatented because the cost is too high to be recovered by sales.
Even if the practical hurdles of funding and enforcing a sequence-publishing policy could be overcome, making unpatented antibody sequences public would allow them to be widely copied, produced and sold. This would eliminate the incentive for good companies to invest in validation. It would also allow 'bad' antibody sequences to contaminate the databases.
The authors' proposal could therefore disproportionately harm the good companies, hurt the end-users it is designed to protect, and would not solve the reproducibility problem. Roberto D. Polakiewicz Cell Signaling Technology, Danvers, Massachusetts, USA. rpolakiewicz@cellsignal.com Biochar: pros must outweigh cons
To optimize the agricultural and environmental benefits of biochar, a charcoal-rich soil additive, we need to overcome its potentially undesirable effects (see Nature 517, 258-260; 2015) .
For example, it is uncertain whether biochar -effectively an underground carbon store -can help to mitigate carbon emissions. A ten-year study of boreal forests found that applying biochar led to soil degradation and increased the activity of soil microbes, causing carbon dioxide release (D. A. Wardle et al. Science 320, 629; 2008) .
Adding blackened biochar can also lower the reflectivity (albedo) of the soil surface, potentially exacerbating climate warming (S. Meyer et al. Environ. Sci. Technol. 46, 12726-12734; 2012) .
Tilling deep furrows in the soil would help to reduce the decline in reflectivity and increase the efficiency of applied biochar. However, this practice could also encourage carbon dioxide release. 
